Commentary

Video

Improving CAR T-Cell Therapy in Multiple Myeloma

Author(s):

Rahul Banerjee, MD

Rahul Banerjee, MD, FACP, of Fred Hutchinson Cancer Center, discusses strategies to improve the benefits of CAR T-cell therapy in multiple myeloma.

Related Videos
Mohamad Mohty, MD, PhD
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM)
Mohamad Mohty, MD, PhD, professor, hematology, Sorbonne University, head, Clinical Hematology and Cellular Therapy Department, Saint-Antoine Hospital
James Ignatz-Hoover, MD, PhD
Bertrand Arnulf, MD, PhD
David Samuel Dicapua Siegel, MD
Philip McCarthy, MD
Robert M. Rifkin, MD, FACP
Noa Biran, MD
María-Victoria Mateos, MD, PhD
Related Content
Ying Huang, PhD
July 2nd 2024

Cilta-Cel Generates OS Benefit in R/R Myeloma After 1 Prior Therapy

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Jakub Svoboda, MD, University of Pennsylvania
June 27th 2024

huCART19-IL18 Is Tolerable, Induces Responses in CAR T-Cell–Pretreated R/R Lymphoma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Jeremy Abramson, MD, of Massachusetts General Hospital
June 27th 2024

Liso-cel Shows Improved EFS, PFS, and Durable Responses in Second-line LBCL at 3 Years

Naresh Bumma, MD, an assistant professor in the Division of Hematology at The Ohio State University Comprehensive Cancer Center—James in Columbus
June 25th 2024

Linvoseltamab Displays Durable Efficacy in Relapsed/Refractory Multiple Myeloma